Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

Novartis Pharmaceuticals

Switzerland
1 Trial

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that has advanced MIJ821 — a selective GluN2B/NR2B NMDA receptor antagonist — through a Phase 2 proof-of-concept trial for treatment-resistant depression, exploring the same ketamine-like NMDA antagonism pathway. MIJ821's rapid-acting antidepressant mechanism is part of Novartis's broader CNS drug discovery pipeline.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Big Pharma
HQ
Switzerland
Website
Visit

Sponsored Trials

1
CompletedII

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Start Date
Compounds
Placebo, Ketamine